{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:58:15Z","timestamp":1790024295505,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jgisurgery.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s11605-016-3270-4","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T13:44:18Z","timestamp":1473947058000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors"],"prefix":"10.1016","volume":"21","author":[{"given":"Laura","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aloia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Nicolas","family":"Vauthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s11605-016-3270-4_bb0010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1007\/s11605-016-3270-4_bb0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/cncr.24065","article-title":"Pancreatic neuroendocrine tumors: the impact of surgical resection on survival","volume":"115","author":"Hill","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0020","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1245\/s10434-014-4016-8","article-title":"Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study","volume":"22","author":"Birnbaum","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1007\/s11605-016-3270-4_bb0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjsurg.2007.01.014","article-title":"Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?","volume":"193","author":"Teh","year":"2007","journal-title":"Am J Surg"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0030","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/archsurg.2011.129","article-title":"Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection","volume":"146","author":"Norton","year":"2011","journal-title":"Arch Surg"},{"key":"10.1007\/s11605-016-3270-4_bb0035","doi-asserted-by":"crossref","unstructured":"Katz, M.H., et al., Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg, 2016: p. e161137.","DOI":"10.1001\/jamasurg.2016.1137"},{"issue":"14","key":"10.1007\/s11605-016-3270-4_bb0040","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1007\/s11605-016-3270-4_bb0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e328344484b","article-title":"Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor","volume":"22","author":"Grande","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1007\/s11605-016-3270-4_bb0050","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience","volume":"73","author":"Yao","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1007\/s11605-016-3270-4_bb0060","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1007\/s11605-016-3270-4_bb0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"21","key":"10.1007\/s11605-016-3270-4_bb0070","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1007\/s11605-016-3270-4_bb0075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1007\/s11605-016-3270-4_bb0080","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1007\/s11605-016-3270-4_bb0085","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1007\/s11605-016-3270-4_bb0090","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0095","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1007\/s11605-016-3270-4_bb0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejca.2003.09.035","article-title":"The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?","volume":"40","author":"Delaunoit","year":"2004","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1007\/s11605-016-3270-4_bb0105","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"issue":"12","key":"10.1007\/s11605-016-3270-4_bb0110","doi-asserted-by":"crossref","first-page":"e0143822","DOI":"10.1371\/journal.pone.0143822","article-title":"Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms\u2014predictive and prognostic markers for treatment stratification","volume":"10","author":"Krug","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000117575","article-title":"Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors","volume":"88","author":"Fjallskog","year":"2008","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6601167","article-title":"Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin","volume":"89","author":"Gonzalez","year":"2003","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1007\/s11605-016-3270-4_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","article-title":"Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors","volume":"27","author":"McCollum","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1007\/s11605-016-3270-4_bb0135","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1245\/s10434-008-9833-1","article-title":"Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer","volume":"15","author":"Hwang","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1007\/s11605-016-3270-4_bb0140","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1007\/s11605-016-3270-4_bb0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11605-013-2374-3","article-title":"Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer","volume":"18","author":"Tran Cao","year":"2014","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10.1007\/s11605-016-3270-4_bb0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.soc.2014.07.002","article-title":"Imaging of pancreatic neoplasms","volume":"23","author":"Balachandran","year":"2014","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1007\/s11605-016-3270-4_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1091-255X(99)80065-1","article-title":"Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis","volume":"3","author":"Bold","year":"1999","journal-title":"J Gastrointest Surg"},{"issue":"15","key":"10.1007\/s11605-016-3270-4_bb0165","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1002\/cncr.26717","article-title":"Histologic tumor involvement of superior mesenteric vein\/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation","volume":"118","author":"Wang","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1007\/s11605-016-3270-4_bb0170","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s11605-015-2914-0","article-title":"Role and operative technique of portal venous tumor thrombectomy in patients with pancreatic neuroendocrine tumors","volume":"19","author":"Prakash","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0175","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"10.1007\/s11605-016-3270-4_bb0180","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"issue":"282","key":"10.1007\/s11605-016-3270-4_bb0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11605-015-2952-7","article-title":"Trends in receipt and timing of multimodality therapy in early-stage pancreatic cancer","volume":"20","author":"Dimou","year":"2016","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"10.1007\/s11605-016-3270-4_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1245\/s10434-011-1945-3","article-title":"Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals","volume":"19","author":"Merkow","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1007\/s11605-016-3270-4_bb0200","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1245\/s10434-015-4714-x","article-title":"Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends","volume":"22","author":"Graham","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1007\/s11605-016-3270-4_bb0205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/1471-2407-14-816","article-title":"Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence\u2014a retrospective analysis over two decades","volume":"14","author":"Wiegering","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"issue":"8","key":"10.1007\/s11605-016-3270-4_bb0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"issue":"13","key":"10.1007\/s11605-016-3270-4_bb0220","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/cncr.25069","article-title":"A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma","volume":"116","author":"McDade","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11605-013-2412-1","article-title":"Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival","volume":"18","author":"Tzeng","year":"2014","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03401399","article-title":"Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?","volume":"15","author":"Perysinakis","year":"2016","journal-title":"Hormones (Athens)"},{"issue":"10","key":"10.1007\/s11605-016-3270-4_bb0235","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ejso.2007.01.030","article-title":"Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma","volume":"33","author":"Sorbye","year":"2007","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000345369","article-title":"Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor","volume":"5","author":"Devata","year":"2012","journal-title":"Case Rep Oncol"},{"issue":"7","key":"10.1007\/s11605-016-3270-4_bb0245","first-page":"1341","article-title":"Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy","volume":"37","author":"Sato","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0250","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0255","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The role of capecitabine\/temozolomide in metastatic neuroendocrine tumors","volume":"21","author":"Ramirez","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0260","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1007\/s11605-016-3270-4_bb0265","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0270","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0275","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"issue":"6","key":"10.1007\/s11605-016-3270-4_bb0280","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s11605-016-3270-4_bb0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00268-006-0585-4","article-title":"Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment","volume":"31","author":"Chung","year":"2007","journal-title":"World J Surg"},{"issue":"11","key":"10.1007\/s11605-016-3270-4_bb0290","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1245\/s10434-014-3769-4","article-title":"Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States","volume":"21","author":"Gratian","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1007\/s11605-016-3270-4_bb0295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11605-014-2624-z","article-title":"Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection","volume":"19","author":"Curran","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"10.1007\/s11605-016-3270-4_bb0300","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3109\/00365521.2016.1170195","article-title":"Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors","volume":"51","author":"Yadav","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1007\/s11605-016-3270-4_bb0305","unstructured":"Singhi, A.D., et al., Alterative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res, 2016."}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11605-016-3270-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23022059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23022059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:50:13Z","timestamp":1761076213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X23022059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1091255X23022059"],"URL":"https:\/\/doi.org\/10.1007\/s11605-016-3270-4","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s11605-016-3270-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Society for Surgery of the Alimentary Tract. Published by ELSEVIER INC. All rights reserved. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}